| abstract |
Charge-stabilized oxygen substantially having an average diameter of less than about 100 nanometers and stably constructed in an ionic aqueous fluid in an amount sufficient to treat a TSLP-mediated or TSLPR-mediated disease or condition Methods are provided for treating a TSLP-mediated or TSLPR-mediated disease or condition comprising the administration of an electrokinetically modified aqueous fluid comprising a nanostructured ionic aqueous solution containing. The charge-stabilized oxygen-containing nanostructure is preferably stably configured in the fluid in an amount sufficient to provide modulation of cell membrane potential and / or conductivity. Certain embodiments, including modulation or downregulation of TSLP expression and / or activity, have utility for treating TSLP-mediated or TSLPR-mediated diseases or conditions as disclosed herein. |